Prescribing for ADHD in primary care

Affiliations

¹ Medical Education and Enterprise, UCL Medical School, London.
² Birmingham, and Visiting Clinical Researcher, Department of Public Health and Primary Care, University of Cambridge, Cambridge.
³ Institute for Applied Health Sciences, University of Birmingham, Birmingham.

Editorial

Ahmed Rashid et al. Br J Gen Pract. 2018 Apr.

. 2018 Apr;68(669):170-171.

doi: 10.3399/bjgp18X695357.

¹ Medical Education and Enterprise, UCL Medical School, London.
² Birmingham, and Visiting Clinical Researcher, Department of Public Health and Primary Care, University of Cambridge, Cambridge.
³ Institute for Applied Health Sciences, University of Birmingham, Birmingham.

No abstract available

References

1. Smith M. Hyperactive around the world? The history of ADHD in global perspective. Soc History Med. 2017;30(4):767–787. - PMC - PubMed
1. Conrad P, Bergey MR. The impending globalization of ADHD: notes on the expansion and growth of a medicalized disorder. Soc Sci Med. 2014;122:31–43. - PubMed
1. Thomas R, Sanders S, Doust J, et al. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4):e994–e1001. - PubMed
1. Beau-Lejdstrom R, Douglas I, Evans SJW, et al. Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open. 2016;6:e010508. - PMC - PubMed
1. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults. CG72. London: NICE; 2008. http://guidance.nice.org.uk/CG72 (accessed 1 Mar 2018)